- Trial phase
- Phase 2a (scheduled to initiate Q1 2027); Phase 1 completed
- Time to market
- At least 3 to 5 years away. The dual combination enters Phase 2a in Q1 2027; a successful Phase 2a and subsequent Phase 3 program plus FDA review would be needed before any approval.
- Why 5/10
- The next hard catalyst is the initiation of the AscenSION CF Phase 2a proof-of-concept trial for the SION-451 + SION-2222 dual combination, expected in Q1 2027 (about 4 months away). This is a milestone event, not a binary readout, and the actual Phase 2a topline data is likely 12+ months further out. ImpactScore of 5 reflects that this is a meaningful milestone for a single-asset company but not a binary catalyst.
The next catalyst is the initiation of the AscenSION CF Phase 2a proof-of-concept trial for the SION-451 + SION-2222 dual combination, expected in Q1 2027. If the trial starts on schedule, it signals the company is executing on its restructuring plan; a delay would raise concerns given the company's single-asset focus. The actual Phase 2a topline readout is likely 12+ months after initiation and represents the true binary event for the stock.
Price Chart
Executive Summary
SION-2222 (galicaftor) is a TMD1-directed CFTR corrector being developed by Sionna Therapeutics (NASDAQ: SION) as part of a dual combination therapy with SION-451 (an NBD1 stabilizer) for cystic fibrosis. The drug completed Phase 1 testing in healthy volunteers with a tolerable safety profile, and the company plans to initiate the AscenSION CF Phase 2a proof-of-concept trial in Q1 2027. This program became Sionna's sole focus after its lead candidate SION-719 failed a Phase 2a trial in August 2026, causing the stock to crash roughly 92% from about $50 to around $3.70. The company cut 46% of its workforce in September 2026 and holds $249.8M in cash funding operations into H2 2029. SION-2222 has never been tested in CF patients, and the dual combination faces the challenge of competing against Vertex's dominant Trikafta franchise.
How It Works
SION-2222 (galicaftor) is a CFTR corrector that targets a specific region of a protein called the transmembrane domain 1 (TMD1). In cystic fibrosis, the CFTR protein is defective and cannot properly transport salt and water in cells. SION-2222 is designed to fix the shape of the CFTR protein so it can function more normally. It is being developed as part of a two-drug combination with SION-451, an NBD1 stabilizer that targets a different part of the same protein, with the goal of providing a standalone treatment for cystic fibrosis that could help patients who do not respond adequately to existing therapies like Vertex's Trikafta.
Trial Status
A Phase 1 healthy-volunteer trial (NCT07035990) evaluated safety, tolerability and pharmacokinetics of SION-451 in dual combination with SION-2222; topline data reported August 10, 2026 showed the SION-451 + SION-2222 cohorts were generally well tolerated with mostly mild-to-moderate adverse events and no serious adverse events, though two participants discontinued due to elevated liver function tests and flu-like symptoms. The AscenSION CF Phase 2a proof-of-concept trial in CF patients is expected to initiate in Q1 2027, supported by post hoc PreciSION CF analyses of SION-719.
The Two-Sided Case
Upcoming Catalysts
- Initiation of the AscenSION CF Phase 2a proof-of-concept trial for SION-451 + SION-2222, expected Q1 2027
- Clinical and nonclinical data presentations at medical conferences (2026 NACFC data already presented)
- Q3 2026 earnings call scheduled around November 11, 2026 (earnings calendar event)
- Any further restructuring, partnership or financing news given the single-asset focus
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sionna Therapeutics, Inc. PRESS-RELEASE SION ·Originating report